Trevena, Inc.
TRVN
Rank in Stocks
#34597
Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and... Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19. TRV250: A G protein-biased delta-opioid receptor agonist under development for the treatment of acute migraine. TRV734: A small molecule G protein-biased MOR ligand designed for the management of both moderate-to-severe acute and chronic pain. TRV045: An innovative S1P modulator focused on providing relief for chronic pain. The company has also established a partnership with Imperial College London to investigate TRV027's potential in patients afflicted with COVID-19. Trevena, Inc., founded in 2007, operates from its headquarters in Chesterbrook, Pennsylvania.
Share Price
$0.0111
Last synced: 2026-11-09
Market Cap
$9.47K
Change (1 day)
0.00%
Change (1 year)
-7.50%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Trevena, Inc. (TRVN)
Category
Healthcare
Operating Margin for Trevena, Inc. (TRVN)
Operating Margin as of November 2026 TTM: -1,129.22%
According to Trevena, Inc.'s latest financial reports, its current operating margin (TTM) is -1,129.22%. At the end of 2023 the company had an operating margin of -1,129.22%.
Operating Margin history for Trevena, Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,129.22% | 0.00% |
| 2023 | -1,129.22% | -108.37% |
| 2022 | 13,486.84% | -247.27% |
| 2021 | -9,157.85% | 853.21% |
| 2020 | -960.74% | -98.88% |
| 2019 | -85,741.94% | 16,014.79% |
| 2018 | -532.07% | 0.00% |
| 2017 | 0.00% | -100.00% |
| 2016 | -2,727.55% | 236.76% |
| 2015 | -809.94% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -17,295.37% | 794.79% |
| 2012 | -1,932.90% | 197.16% |
| 2011 | -650.46% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.03% |
US
|
|
| -149.01% | -99.87% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.03% |
BE
|
|
| 29.35% | -100.03% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Trevena, Inc.'s operating margin
What is Trevena, Inc.'s operating margin?
Trevena, Inc.'s operating margin is -1,129.22%, as of Nov 2026.
What was Trevena, Inc.'s operating margin in 2023?
In 2023, Trevena, Inc.'s operating margin was -1,129.22%, compared with 13,486.84% in 2022.
How has Trevena, Inc.'s operating margin changed since 2018?
From 2018 to 2023, Trevena, Inc.'s operating margin was highest in 2022 (13,486.84%) and lowest in 2019 (-85,741.94%).
How does Trevena, Inc.'s operating margin compare with similar companies?
Trevena, Inc.'s operating margin (-1,129.22%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.